Iodine leads the AI-powered mid-revenue cycle solutions market, empowering hospitals to unlock immediate financial gains and streamline operations. The company was acquired by Waystar Health in October 2025, positioning it within a larger healthcare payments ecosystem.
Cyborg Score Rationale
Market leader in healthcare AI with proven customer base of 1,000+ hospitals, significant valuation ($1.25B acquisition), and integration into major healthcare payments platform. Loss of independence post-acquisition limits autonomous growth potential.
Top Insights
Acquired by Waystar Health in October 2025 for $1.25 billion enterprise value, consolidating clinical intelligence with revenue cycle management
Product suite has helped ~500 hospitals recognize $1.5 billion in additional appropriate reimbursement annually, demonstrating measurable ROI
Uses AI and machine learning algorithms with predictive engines to interpret clinical data and automate workflows, serving enterprise healthcare customers
Backed by institutional investors including Advent International, Bain Capital Ventures, Silversmith Capital Partners, strong financial backing
Named Competitors
Innovaccer — Healthcare data platform
Inovalon Holdings — Healthcare IT and data analytics
Greenway Health — Healthcare EHR and practice management software
Trella Health — Clinical revenue optimization
Recent Developments
(October 2025) Acquired by Waystar Health for $1.25 billion enterprise value, combining clinical AI with healthcare payments platform
(July 2025) Announced definitive acquisition agreement with 50/50 cash-stock consideration structure
Open the full interactive Iodine Software report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.